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Abstract
Complement factor H shows very strong association with Age-related Macular Degeneration (AMD), and recent data suggest
that multiple causal variants are associated with disease. To refine the location of the disease associated variants, we
characterizedindetailthestructuralvariationatCFHanditsparalogs,includingtwocopynumberpolymorphisms(CNP),CNP147
and CNP148, and several rare deletions and duplications. Examination of 34 AMD-enriched extended families (N=293) and AMD
cases (White N=4210 Indian=134; Malay=140) and controls (White N=3229; Indian=117; Malay=2390) demonstrated that
deletion CNP148 was protective against AMD, independent of SNPs at CFH. Regression analysis of seven common haplotypes
showed three haplotypes, H1, H6 and H7, as conferring risk for AMD development. Being the most common haplotype H1
confers the greatest risk by increasing the odds of AMD by 2.75-fold (95% CI=[2.51, 3.01]; p=8.31610
2109); Caucasian (H6) and
Indian-specific(H7)recombinanthaplotypesincreasetheoddsofAMDby1.85-fold(p=3.52610
29)andby15.57-fold(P=0.007),
respectively.Weidentified a 32-kbregiondownstreamof Y402H (rs1061170), shared byallthreerisk haplotypes,suggesting that
this region may be critical for AMD development. Further analysis showed that two SNPs within the 32 kb block, rs1329428 and
rs203687, optimally explain disease association. rs1329428 resides in 20 kb unique sequence block, but rs203687 resides in a
12 kb block that is 89% similar to a noncoding region contained in DCNP148. We conclude that causal variation in this region
potentially encompasses both regulatory effects at single markers and copy number.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of
visual dysfunction and blindness in developed countries, and a
rising cause in underdeveloped countries. In the United States
(US), its prevalence in the population over age 65 years is 9% and
increases to 28% in those over 75 years [1]. AMD is characterized
by progressive degeneration of the macula, causing central field
vision loss. A characteristic feature of AMD is the formation of
deposits in the macula, called drusen, which may progress to either
geographic atrophy or subretinal neovascularization, manifesta-
tions of late AMD. Several genetic and environmental risk factors
influence disease susceptibility [2,3]. Genes involved in the
complement pathway have especially been implicated in disease
pathogenesis [4,5,6,7,8,9,10,11,12,13].
A major locus for AMD pathogenesis, CFH, was identified
through linkage and Genome-wide association studies (GWAS)
[4,8,9]. A nonsynonymous single nucleotide polymorphism (SNP)
in CFH, rs1061170 (also known as Y402H), was proposed as the
major risk variant with odds ratios ranging from 1.4 to 7.4
(reviewed in Patel et al. [14]). In the contiguous region, a common
deletion involving CFHR3 and CFHR1 was also shown to confer
protection against AMD [15]. However, deeper analysis of the
data led to CFH intronic SNPs being more significantly associated
with AMD than rs1061170 [16,17], suggesting that other
unidentified variants play an important role in disease pathogen-
esis. We therefore systematically examined SNPs and structural
variation in the CFH region and propose a unifying hypothesis for
AMD risk.
Results
Structural Variation at the RCA Gene Cluster
Our initial examination of the genomic sequence between CFH
and CFHR5 revealed duplicated segments, including several novel,
highly similar, homologous regions (Figure S1, Text S1 and Table
S1). In general, the high sequence identity among duplicated
regions increases the probability of structural rearrangements due
to non-allelic homologous recombination. None of the previous
studies thoroughly screened the RCA gene cluster for structural
variation, or considered copy number information and SNPs
together to identify causal variants at CFH. Therefore, we
conducted a detailed survey of the structural variation in 1582
reference samples. This revealed existence of two CNPs, CNP147
and CNP148, in addition to several rare copy number variations
(CNVs) in the RCA gene cluster (Figure 1a–d and Table S2). Both
CNPs most often carry deletions rather than duplications, and the
frequencies of these deletions vary among different reference
populations (Table S3). We validated these CNPs in the reference
samples using fosmid pair-end sequencing, array comparative
genomic hybridization (CGH), depth of coverage analysis of
genomic sequence, and a PCR based deletion screening strategy
(Figure 2a, Figures S2 and S3). Finally, we sequenced the two
deletion variants, after subcloning them in fosmid clones [18]
(Figure 2b, 2c), which provided single basepair resolution for each
deletion. The deletion at CNP147 (DCNP147) was about 86.3 kb
(chr1:194,988,828–195,075,129,NationalCenterforBiotechnology
Information (NCBI) build 36), although it was earlier reported to be
about 84.6 kb [15], and included CFHR3 and CFHR1. The distal
deletion at CNP148 (DCNP148) spanned 122.0 kb, encompassing
CFHR1 and CFHR4 (chr1:195,049,336–195,171,294, NCBI build
36).
We further determined the ancestral origin of these CNPs using
phylogenetic and linkage disequilibrium (LD) analysis, which
demonstrated that these common deletions were recurrent in
origin in Africans, although the results showed a single ancestral
origin of DCNP147 in Caucasians and Asians (Figure 3a and
Figure S4). Since DCNP147 in Caucasians resides on an ancestral
haplotype, we were able to find perfect correlation (r
2=1) between
DCNP147 and SNPs in the surrounding region, i.e., rs6677604,
rs12144939, rs7542235, rs16840639 and rs2996127. Though
perfect LD between rs6677604 and DCNP147 has been reported
before [15,19,20], we found the exact extended haplotypic
background on which the deletion occurred. We did not observe
LD between DCNP148 and any nearby SNPs.
A 32 kb Region in CFH is Important for AMD Risk
We sought to determine the causal variant(s) in clinical samples
including 34 extended families and a non-familial dataset
consisting of 4484 cases and 5736 controls from three different
populations. We first determined the copy number at CNP147
and CNP148 using microarray intensity data. Direct assessment of
copy numbers at CNP147 was not possible in the clinical samples,
except in the Familial Age-related Maculopathy Study (FARMS)
cohort, due to low probe coverage in many of the commercial
arrays in this region. We, therefore, used tag SNPs to predict the
deletions at CNP147. Predicted homozygous deletions were
validated with PCR-based deletion screening (Figures S5 and
S6). We constructed the haplotypes using SNP and CNP147
genotype data. We did not include CNP148 in the haplotype
analysis because it is rare and occurred on multiple haplotypic
backgrounds.
Haplotype analyses revealed six different common haplotypes
(defined as present at a frequency of .1% in the samples) in the
Caucasian datasets (Figure 3b). Using the H2 haplotype as
baseline because it carried neither DCNP147 nor the C risk allele
at codon 402 of CFH, we assessed the effect of all other haplotypes
(Table 1, 2 and Table S4). The results showed that the most
common H1 haplotype conferred the greatest risk relative to H2
by increasing the odds of AMD by 2.75-fold (95% CI=[2.51,
3.01], p=8.31610
2109) in the Caucasian non-family cohorts.
Haplotypes H3 and H4 with DCNP147 were found to confer
protection against AMD over and above the base H2 haplotype
(OR=0.74 p=1.83610
25; and OR=0.70, p=2.81610
24),
demonstrating that the deletions are indeed protective. H3 and
H4 are virtually identical to H2 with the exception of the presence
of DCNP147; phylogenetic analysis suggests that DCNP147 may
have originated on the H2 background (Figure S4).
We also identified a recombinant haplotype (H6), with a
frequency of ,4%, which conferred risk for AMD (OR=1.85;
p=3.52610
29). Since this recombinant haplotype excludes most
of the LD block 1 that carries codon 402, it was crucial in reducing
the AMD-associated interval to a 32-kb block, not including
rs1061170. We also found another haplotype, H5, without the C
allele at rs1061170, that confers risk for AMD (OR 1.54;
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213) over the H2 haplotype; however, the frequency
of H5 haplotype is more in controls than cases. Analysis of each
haplotype independent of H2 as baseline showed H5 a neutral
haplotype, with OR not significantly different from 1 (data not
shown). Unlike H1 or H6, which carried the same core 32-kb
haplotype between markers rs9970784 and rs70620, H5 showed
some differences but also carried many of the same risk alleles in
the 32-kb core. Thus, it is not clear whether H5 is causal or neutral
in the general population; additional studies are needed to confirm
its role in the disease pathogenesis. The final support for the 32-kb
critical region came from the Indian cohort, where another
uncommon, possible recombinant, haplotype (H7) conferred risk
for AMD (OR=15.57; p=0.007). In this case, a recombination
event occurred between rs1061170 and rs10801555, but the rest of
the haplotype was identical to the 32 kb core risk haplotype
present in H1 and H6.
rs1329428 and rs203687 are the best SNPs of AMD-
association at CFH
Traditional single SNP-disease association analyses showed
consistently strong signals, which created an unusually wide
footprint, from CFH to ZBTB41 (Figure 4 and Table S5). This
observation is potentially due to suppression of recombination as a
result of structural variation between the RCA gene cluster
haplotypes. In agreement with our haplotype results, the majority
of SNPs in the 32 kb critical region showed very strong association
with AMD (10
245,p,10
2133). Li et al. [16] and Maller et al. [17]
first showed that several SNPs in this region were more strongly
associated with AMD than rs1061170; among the best ranked
variants in these earlier reports were rs2274700 and rs1410996,
respectively.
To select a minimal set of SNPs that explain the effect of CFH on
AMD, we used forward selection while restricting our analysis to the
32 kb region for which all risk haplotypes have support. We
identified rs1329428 and rs203687 as the markers showing best
evidence for association with AMD. These SNPs entered the models
with p-values=2.6610
2105, and 8.7610
214, respectively. After this,
the model was saturated and no other SNPs entered the model. Both
these variants are located in non-coding intronic regions (intron 15
and 9, with r
2=0.553, respectively) and are in moderate LD with
rs1061170 (r
2=0.315 and 0.574, respectively). These variants have
beenshowntobindtotranscriptionalregulatoryproteins(FigureS7).
Bioinformatic analyses predict that the variant allele ‘‘T’’ at
rs203687 abolishes binding sites for RE-BP1 and CBP100 and
creates two new sites, for NF-1 and Oct-1. However, analysis of
HapMap gene expression data showed no significant changes in
Figure 1. Detection of CNPs in the reference samples. (1a) Schematic diagram showing the location of the genes and segmental duplications
in the RCA gene cluster. Distal areas that are highly similar to one another are represented using the same color. (1b) Heat map showing normalized
probe intensities in 90 HapMap Yoruban (YRI) samples. Yellow indicates the high probe intensity and red indicates low intensity; clustering of low
intensity (red) occurs in regions with CNP 147 and CNP 148. Black vertical lines denote the boundaries of the region that incorporates CNP147 and
CNP148. (1c) and (1d) Genotypes of CNP147 and CNP178, respectively, across different reference groups. y axis is probe intensity and x axis is
reference groups (see Table S3 for CNP genotype frequencies); AA: Coriell African American, CAU: Coriell Caucasian, CHI: Coriell Chinese, MEX: Coriell
Mexicans, ASN: HapMap Asian, CEU: HapMap Caucasian, YRI: HapMap Yorubans.
doi:10.1371/journal.pone.0025598.g001
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rs1329428 and rs203687. Evaluation of these SNPs in the retinal
cells isneeded togaugethe importanceofthese sites inthe regulation
of the CFH gene expression. It is also possible that these variants are
in LD with the actual causal variant. Exploring this 32 kb region
using next-generation resequencing and expression tools would be
helpful in understanding the causal variants at this locus.
DCNP148 is Independently Associated with AMD
We sought to determine whether the common deletions at
CNP147 and CNP148 confer protection independent of SNPs at
CFH, and conducted logistic regression with and without
rs1329428 and rs203687 as covariates. Without inclusion of the
most signficiant SNPs, an increase in the copy number at CNP147
shows a trend towards the risk. After inclusion of these markers,
the p-value at DCNP147 did not reach significance (p.0.05)
(Tables 3, 4 and S6). These results suggest that the effect at
DCNP147 is not independent of the markers at CFH.I n
supporting this, Raychaudhuri et al. [21] and Fritsche et al. [22]
showed marginal significance of AMD with DCNP147 after
adjusting for key SNPs such as rs1061170 and rs10737680 or
rs2274700 (p=0.02 and 0.044, respectively). One possible
explanation for this trend may be due to occurrence of DCNP147
on the H2 background, and the modest LD between CNP147 and
rs1329428 and rs203687 (r
2=0.462 and 0.261, respectively).
Additional studies of DCNP147 occurring on other haplotypes are
needed to confirm these results.
Interestingly, the presence of additional copies of CNP148
conferred risk for AMD after even adjusting for the effect of the
two best SNPs at CFH (OR 2.24; p=0.0023 and ß=1.11; and
p=0.03, respectively in the custom Illumina panel and the
FARMS samples), suggesting that DCNP148 confers protection
against AMD independent of SNPs at CFH.
Discussion
We systematically examined the CFH region to categorize
variants responsible for AMD pathogenesis using multiple datasets
Figure 2. Validation of CNPs in the HapMap samples. (2a) UCSC browser view (http://humanparalogy.gs.washington.edu/) showing
organization and structural variation in the RCA gene cluster. Red bars indicate the sites of structural variation in eight individuals underwent fosmid
pair-end sequencing. Deletions at CNP147 and CNP148 were using high-resolution tiling-path custom array-based CGH. Probes with log2 ratios
below or above a threshold of 1.5 s.d. from the normalized mean log2 ratio are colored red (deletions) or green (duplication), respectively. (2b) and
(2c) Alignment of sequenced fosmid inserts against the human genome assembly (build36) confirms the extent of two deletions in the CFHR cluster
on chromosome 1. Clone AC213924, derived from sample NA18507, corresponds to deletion CNP147 (2b). This variant removes 86.3 kbp of sequence
(chr1:194,988,828–195,075,129, build36), resulting in loss of CFHR3 and CFHR1 genes. Clone AC210432, derived from sample NA18956, corresponds to
deletion CNP148 (2c). This variant removes 122.0 kbp of sequence (chr1:195,049,336–195,171,294), resulting in loss of CFHR1 and CFHR4 genes. Red
boxes: RefSeq transcripts, with orientation indicated by arrows. Grey boxes: regions of segmental duplication as predicted by SegDup Masker.
Common repeats were identified using Repeat Masker. Purple: SINEs, Green: LINEs, Pink: DNA elements, Light Grey: Low Complexity sequence, Black:
Simple Repeats.
doi:10.1371/journal.pone.0025598.g002
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25598Figure 3. Haplotypes and linkage disequilibrium (LD) in the region surrounding CNP147. (a) Distribution of r
2 and D9 values for SNPs with
CNP147 in three HapMap populations. The squares represent the D9 values while the triangles indicate the r
2 values. Different shades of squares and
triangles indicate weak (light shade) to strong LD (dark shade). DCNP147 shows perfect LD with nearby SNPs in non-Africans. The arrows indicate the
SNPs used as a proxy to predict DCNP147 in our AMD custom Illumina panel. (b) Haplotypes in the CFH region observed in clinical cohorts.
Haplotypes were constructed from genotypes of 70 SNPs located in the CFH region using PHASE2.1.1. Location and alleles of key selected SNPs are
given here for expediency. The risk-associated allele at each locus is shown in red and the protective alleles at the corresponding locus are in blue.
The bottom panel shows the location of CNP147 and CNP148. DCNP147 is indicated by a thin black line in haplotypes H3 and H4. Except H3 and H4,
all haplotypes carry normal constitution at CNP147. The critical region, wherein the putative AMD susceptibility variant lies, is enclosed in black box
for clarity and the two best SNPs rs203687 and rs1329428 are highlighted in pink. H1 and H6 are risk bearing, and H2–H4 are protective in nature. The
role of H5, which carries risk alleles at several loci in block2 in causing disease is not clear. The Indian cohort has a rare risk recombinant haplotype H7,
with non-risk allele T at rs1061170 present in 4% of the chromosomes. The most common risk haplotype among the Indians was equivalent to H1 as
seen in Caucasians.
doi:10.1371/journal.pone.0025598.g003
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and SNPs in the RCA gene cluster, and then assessed their effect
on AMD pathogenesis. We identified two common deletions:
DCNP147, which removes all of CFHR3 and CFHR1, and
DCNP148, which removes CFHR1 and CFHR4 in addition to a
large segment of flanking non-coding sequence. Our results show
that DCNP148, a rarer deletion that occurs on variety of
haplotype backgrounds, appears to confer protection against
AMD in addition to SNPs at the CFH locus. The protection
conferred by this deletion may be due to reduction or absence of
the CFH-related protein products (CFHR1 or CFHR4), or
alternatively, regulatory sequence in the deleted region may have
a significant impact on disease pathogenesis. The C-terminal
regions of CFHR3, CFHR1 and CFHR4 exhibit considerable
homology with CFH SCRs 18–20, enabling them to compete with
CFH for binding to C3b [23], In addition, CFHR1 also competes
with CFH for cell surface attachment in the process of inhibition of
C5 convertase and terminal complex formation [24]. This leads to
a reduction in inhibition of C3 convertase and anti-inflammatory
activity, which results in host cell damage [24,25]. In the absence
of CFHR1 (CFHR4), local CFH binding and activity is increased
resulting in enhanced iC3b deposition and likely phagocytosis of
opsonized particles, which may be advantageous for the clearance
of cellular debris in the retina [21].
The area between CFHR1-CFHR4 seems particularly vulnerable
to recurrent rearrangements when evolutionary history is examined
in conjunction with human-specific comparisons. Comparative
primate genome analysis shows that chimpanzees have more
extensive duplication architecture at the RCA locus than humans.
Targeted array CGH of the region confirms increase of CFHR
copies in the chimpanzee and the bonobo when compared to
human, but the orangutan has reduced copy-number (Figure S8).
Interestingly, a portion of CFHR4 seems to have hyper-expanded in
the great apes (bonobo and orangutan). Drusen formation, a
precursor to sight-threatening late AMD, is polymorphic in the Old
World monkey, the rhesus macaque [26]. Macaques diverged from
the common ancestor to humans approximately 25 million years
ago, and the shared phenotypic features of retinal drusen formation
in humans and macaques suggest that the mechanism is old and
evolutionarily preserved. As described in the results, the core
sequence containing AMD disease susceptibility variants shows
significant homology with CFHR1-CFHR4. These duplicated tracks
will need to be examined in greater molecular detail to characterize
the exact causal mechanism.
Within human samples, we observed over 25 rare structural
variant events in the RCA gene cluster in a sample size of 1875
individuals (1582 reference and 293 clinical) using high resolution
SNP arrays (Tables S2 and S7). The majority of these events are
smaller than 25 kb in size. About half of them are losses, affecting
intergenic regions of CFH-related genes. Four of the rare events
found in FARMS arelarger than 25 kb.Twoaredeletionsobserved
in a single individual. Since these events were de novo in nature, we
were unable to predict whether they occurred on the same
chromosome or on opposite homologs based on the information
from the arrays alone (Table S7). The smaller of these two deletions
results in the loss of the region encompassing exons 10–16 of CFH.
Although we cannot be certain, this effect is likely to increase
susceptibilityto AMDbecause the core variant(s)causing disease lies
within the boundaries of this deletion. The larger deletion of 209 kb
removes one of the copies of CFHR1, CFHR4, CFHR2 and part of
CFHR5. The effect of the latterdeletion is likely to be protective, but
its impact is currently unknown because the deletion extends far
beyond DCNP148. The participant carrying both deletions is only
45 years old, when incipient disease is not yet apparent. This
individual has an average score of 2 on the Wisconsin age-related
maculopathy grading system (WARMGS) score, which is approx-
imately equal to having retinal hard distinct drusen ,63 mmi n
diameter [27]. Supporting the hypothesis of recurrent rearrange-
ments, a rare, large deletion, involving CFH-CFHR1, causing
atypical hemolytic uremic syndrome has also been reported before
[25]. This deletion, with breakpoints within the last three exons of
CFH and CFHR1, results in a hybrid CFH-CFHR1 protein, which
leads to atypical hemolytic uremic syndrome as a result of defective
recognition function.
Our analysis of the reference HapMap samples and several
large clinical datasets suggests that the critical AMD region of risk
spans 32 kb that is not dependent on the presence of rs1061170.
Based on haplotypes derived from five SNPs, Li et al. [16] showed
that ,6% of risk haplotypes lack the ‘‘C’’ allele at codon 402. We
conducted haplotype analysis using 78 informative SNPs and
found the H6 haplotype, which bore a recombinant that separated
codon 402 from the core risk haplotype. The plausibility of
rs1061170 as the AMD causal variant was originally put forward
by Edwards et al. [4] and Haines et al. [8] when high resolution
arrays with copy number information were not commercially
available. This variant remained a strong contender because of its
efficacy as a tag, and the weight of the biological evidence, e.g.,
due to its interaction with C-reactive protein, an important specific
marker of inflammation [28]. Recently, Hakobyan et al. [29]
developed monoclonal antibodies for allele-specific factor H levels
assayed in plasma. Their data show that factor H levels increase
with age, but that there is lack of correlation between plasma levels
by genotype and AMD status; the authors attribute these
discrepancies to other factors e.g. smoking. We also observed no
evolutionary conservation either at tyrosine or histidine when
comparing the orthologous sequence (Figure S9). In considering
the sum of evidence, we put forward that rs1061170 may only be
causal in the context of the 32 kb critical region, which harbors the
two best signals at rs1329428 and rs203687.
An interesting feature of the 32 kb sequence is that it can be
partitioned into a 12 kb segmentally duplicated block and a 20 kb
unique region. rs203687 maps to the segmentally duplicated block,
while rs1329428 maps to the unique sequence. The segmental
duplication shows 89% homology with the noncoding region
between CFHR1 and CFHR4 which contains DCNP 148,
suggesting that the protection offered by this deletion variant
may be directly mediated through this similarity. The LD between
rs1329428 and rs203687 is modest (r
2=0.57). rs2274700, earlier
reported by Li et al. [16], localizes to the segmental duplication
block, while rs1410996, reported by Maller et al. [17], maps to the
unique fragment at intron 14. In the HapMap CEU data, the LD
between rs1329428 and rs1410996 is perfect (r
2=1). The results
Table 1. Association of CFH haplotypes in the FARMS cohort.
Haplotype Association
Haplotype Frequency Effect LRT p-value
H1 0.5189 0.657 9.46610
205
H2 0.1065 Base -
H3 0.067 20.279 0.272
H4 0.0206 20.293 0.485
H5 0.1615 20.008 0.714
H6 0.0653 0.467 0.082
doi:10.1371/journal.pone.0025598.t001
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Haplotype Frequency Haplotype Association
@
Cohort Haplotype Cases Controls Total OR 95% CI p-value
Custom Illumina Panel* H1 0.5152 0.3263 0.4210
$ 2.25 1.96, 2.58 1.35610
230
H2 0.1061 0.1916 0.1488
$ Base - -
H3 0.0611 0.1205 0.0908
$ 0.70 0.56, 0.87 1.15610
203
H4 0.0285 0.0624 0.0454
$ 0.61 0.46, 0.82 8.49610
204
H5 0.1459 0.1416 0.1438
$ 1.46 1.21, 1.75 6.93610
205
H6 0.0379 0.0322 0.0351
$ 1.83 1.33, 2.54 2.42610
204
MPM Panel
# H1 0.5802 0.3317 0.4878 3.35 2.91, 3.86 1.73610
262
H2 0.0888 0.2000 0.131 Base - -
H3 0.0593 0.1230 0.0832 0.89 0.73, 1.10 0.275
H4 0.0209 0.0548 0.0336 0.80 0.59, 1.08 0.143
H5 0.1435 0.1570 0.1477 1.73 1.45, 2.06 6.24610
210
H6 0.0359 0.0322 0.0353 2.19 1.61, 2.99 2.42610
207
AREDS H1 0.5855 0.3193 0.499 2.45 1.76, 3.41 9.70610
208
H2 0.0768 0.1566 0.1027 Base - -
H3 0.0536 0.1687 0.091 0.43 0.26, 0.71 0.001
H4 0.0130 0.0392 0.0215 0.48 0.19, 1.22 0.120
H5 0.1174 0.1386 0.1243 1.06 0.65, 1.719 0.830
H6 0.0333 0.0211 0.0294 2.27 0.89, 5.79 0.087
Indian H1 0.4291 0.2391 0.3414 2.05 1.27, 3.30 0.003
H2 0.0597 0.1696 0.1104 Base - -
H3 0.0746 0.1391 0.1044 0.63 0.31, 1.26 0.190
H4 0.0858 0.1870 0.1325 0.54 0.28, 1.07 0.078
H5 0.0858 0.1217 0.1024 0.59 0.29, 1.22 0.150
H7 0.0672 0.0043 0.0382 15.57 2.12, 114.30 0.007
SiMES H1 0.0786 0.0768 0.0767 0.99 0.62, 1.57 0.950
H2 0.4286 0.4161 0.4176 Base - -
H3 0.0143 0.0100 0.0102 1.69 0.58, 4.90 0.340
H4 0.0357 0.0393 0.0389 0.92 0.47, 1.80 0.800
H5 0.3893 0.4013 0.4003 0.99 0.76, 1.29 0.950
Meta CC
1 H1 2.75 2.51, 3.01 8.31610
2109
H2 Base - -
H3 0.74 0.65, 0.85 1.83610
205
H4 0.70 0.58, 0.85 2.81610
204
H5 1.54 1.37, 1.73 1.73610
213
H6 1.85 1.51, 2.27 3.52610
209
Meta All
2 H1 2.00610
290
H2 Base
H3 8.07610
205
H4 0.003
H5 1.44610
210
H6 4.52610
209
*Odds ratio and p-values obtained from meta-analysis is given here and the results from the individual cohorts are seen in the Table S4.
$Frequency from the pooled data (all cohorts).
#Results from the pooled data.
@Association using H2 haplotype as baseline, adjusted for covariates described in Table S8.
1Meta analysis of all Caucasians non-familial cohorts.
2Meta analysis of all Caucasian cohorts (non-family cohorts and family cohort in Table 2) and p-value indicates the Fisher p-value.
doi:10.1371/journal.pone.0025598.t002
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25598Figure 4. The strength of the association signal, as indicated by 2log(p value) on the Y-axis, is plotted against SNP location on
chromosome 1 on the X-axis. The (A) panel shows the p-values from individual clinical cohorts which are labeled in different colors and shapes
(see Labels). The SNPs located within the 32 kb critical region show the best association signal in the 6 clinical datasets. Panel (B) shows the
distribution of pair-wise linkage disequilibrium (D9) values between CFH and ZBTB41. The LD blocks are marked with black triangles; red indicates D9
values of 1 (complete LD) while white indicates D9 values of 0 (no LD whatsoever).
doi:10.1371/journal.pone.0025598.g004
Table 3. Association of DCNP147 with AMD, with and without inclusion of rs1329428 and rs203687, as covariates.
DCNP147 Frequency DCNP147 association with AMD
$ DCNP147 association with AMD@
Cohorts Cases Controls OR 95% CI p-value OR 95% CI p-value
Custom Illumina
1 – Meta-analysis 0.1052
# 0.2119
# 2.21 1.90, 2.58 4.50610
224 1.12 0.92, 1.37 0.24
MPM Panel
2 0.0948 0.2074 2.47 2.11, 2.88 2.77610
230 1.04 0.85, 1.27 0.72
AREDS
3 0.0855 0.2314 3.23 2.22, 4.72 1.89610
29 1.41 0.87, 2.29 0.16
Meta-analysis* — — 2.34 2.10, 2.61 1.33610
252 1.10 0.96, 1.26 0.15
Indian
4 0.2129 0.3675 2.06 1.35, 3.14 7.74610
24 NA NA NA
SiMES
2 0.0504 0.0649 1.47 0.53, 4.08 0.46 NA NA NA
#Frequencies obtained from the pooled data.
$After adjusting for significant covariates as described in Table S8.
@After adjusting for rs1329428 and rs203687, in addition to significant covariates as described in Table S8.
*Meta-analysis of the Custom illumina panel, MPM panel and AREDS cohort.
1DCNP147 predicted by A-G-C haplotype at rs6677604, rs7542235 and rs16840639.
2DCNP147 predicted by ‘‘A’’ allele at rs6677604.
3Since none of the DCNP147-specific SNPs are genotyped in AREDS,the ‘‘A’’ allele at rs2019727 that is highly correlated (r
2=0.9) with this deletion in the Caucasians was
used as proxy.
4DCNP147 predicted by the ‘‘G’’ allele at rs7542235.
NA - not adjusted for rs1329428 and rs203687 as their genotypes are not available.
doi:10.1371/journal.pone.0025598.t003
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statistically determine which variant is causal. The region with the
best signal contains complement control protein modules 12–14, a
putative C3b/C3c binding site [30]. The important finding is that
thecore sequence containingthe AMDsusceptibilityvariant(s)hasa
complex structure affecting both copy number and gene regulation.
In summary, we have expanded the knowledge base of the
spectrum of genetic variation at the CFH locus and its paralogs;
CFH was the first gene with a common variant to be identified
through GWAS. As with loci that function in immunity cascades,
these genes show signs of positive selection and recurrent
rearrangements, an attribute of CNVs. We also circumscribed a
critical region within CFH that carry AMD risk-causing variants.
The AMD field has begun to apply the original gene-mediated risk
profiles towards personalized medicine. Maller et al. [17] proposed
assessing lifetime risk of AMD by evaluating five common SNPs at
CFH, ARMS2, C2 and CFB, and ranking risk by counting the
number of susceptibility variants at each locus. Seddon et al. [31]
have shown that the predictive power for AMD progression at six
SNPs in these genes along with demographic profiles is over 82%.
However, our results show that common and rare deletions,
duplications, and rearrangements are complex phenomena that
may lead to unanticipated results, particularly when the net
consequence of the diplotype across both homologs is taken into
consideration. CFH has similarly been the focus of examination for
atypical hemolytic uremic syndrome and Membranoproliferative
Glomerulonephritis type II (MPGN II). Expansion of the
repertoire of variation at the expanded RCA locus will have an
impact on the predictive ability for both diseases, AMD and
MPGN/atypical hemolytic uremic syndrome, with more compre-
hensive models being required for forecasting future disease status.
We suggest that a systematic survey of larger clinical datasets is
needed to understand the role of these common and rare events in
mediating susceptibility and protection.
Materials and Methods
Ethics Statement
This study was approved by the Institutional Review Boards of
the Case Western Reserve University, Cleveland; University of
Wisconsin, Madison; University of Michigan, Ann Arbor; Cleve-
land VA Medical Center, Cleveland; Cleveland Clinic Foundation;
Cleveland; Mayo Clinic, Rochester; University of Pennsylvania,
Philadelphia; Oregon Health & Sciences University, Portland;
Singapore Eye Research Institute, Singapore; and ethics sub-
committee of the Vision Research Foundation, Chennai, India.
Subjects
Reference Sets. The reference sets include 270 phase I+II
HapMap samples (30 Utah residents of Northern and Western
European ancestry (CEU) trios, 30 Yoruba in Ibadan (YRI) trios,
45 Han Chinese in Beijing (CHB) and 45 Japanese in Tokyo (JPT))
and 912 HapMap phase III samples, belonging to 11 different
populations (CEU, CHB, JPT, YRI, Chinese in Denver, Gujarati
Indians in Houston, Luhya in Webuye, Kenya, Mexicans in Los
Angeles, Maasai in Kinyawa, Kenya, Tuscans in Italy and
Africans in Southwest USA. We also examined 400 samples,
comprising 100 each of African Americans, Caucasians, Chinese
and Mexicans, belonging to the Human Variation Panel from the
Coriell Institute for Medical Research (Coriell, NJ, USA). The raw
intensity files (Affymetrix genome-wide Human SNP6.0 array) of
all these samples were obtained directly from Affymetrix (Santa
Clara, CA), http://www.hapmap.org and the Coriell Institute for
Medical Research (Camden, NJ), respectively.
Clinical Sets. Our clinical datasets include 293 individuals
from 34 families participating in Familial Age-related Maculopathy
Study(FARMS),600casesand controls (400 casesand200 controls)
participating in the Age-related Eye disease study (AREDS), a
Michigan-Penn-Mayo (MPM) Panel containing of 2157 cases and
1150 controls,a South Indiancohortwith 251 individuals(134 cases
and 117 controls) and the Singapore Malay Eye Study (SiMES)
cohort containing 3072 samples on whom GWAS data was
available (Figure S10 and Table S8 for details of cohort pheno-
typing and genotyping). In addition to the GWAS data, a panel of
1941 severe cases and 1991 controls from five different cohorts
(referred to as the custom Illumina panel) were also examined using
custom genotyping. The description of the clinical sets is presented
inTextS2andTableS8.Thisstudywasconductedaccordingtothe
principles expressedin the Declaration of Helsinki. Allsamples were
collected according to institutionally approved protocols for study of
human subjects at the respective Institute and written informed
consent was obtained from all subjects.
Sequence Similarity Search
To detect similar segments in the RCA gene cluster, we
obtained genomic sequence of this region (NCBI build 36; http://
www.ensembl.org) and used Megablast search option in the Basic
Local Alignment Search Tool (BLAST) at NCBI. In primates, the
segmental duplications were detected using the whole-genome
shotgun sequence detection approach [32]. The strategy entails
the alignment of orangutan and chimpanzee whole genome
shotgun reads using the Megablast program and identifying
regions with a statistically significant excess read depth (see
Marques-Bonet et al. [33] for details).
Genotyping and Quality Control
The DNA samples used in this study were genotyped with a
variety of platforms. The genotyping methods as well as quality
control criteria are described in Table S8.
Table 4. CNP association in the FARMS cohort.
Association of CNPs with AMD
$ Association of CNPs with AMD@
CNP Effect SE LRT p-value Effect SE LRT p-value
CNP147* 0.689 0.182 0.0002 0.42 0.23 0.07
CNP148* 1.260 0.520 0.016 1.110 0.310 0.03
*Increase in every copy at of the CNP with increase in the AMD score.
$Association of CNPs after adjusting for age and age
2.
@Association of CNPs after adjusting for age, age
2, rs1329428, and rs203687.
doi:10.1371/journal.pone.0025598.t004
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placed in the whole genome arrays or in the GoldenGate custom
Illumina genotyping array. Thus, this variant was genotyped in the
FARMS, AREDS, the custom Illumina panel and Indian cohort
using a custom assay (Applied Biosystems, Foster City, CA) or
direct sequencing. Results for the FARMS rs1061170 data are
published elsewhere [10,34].
Copy Number Variation (CNV) Detection
Copy number variant detection was performed by different
methods depending on the available genotyping platform (Table
S8). The common and rare copy number variations were detected
using the Birdsuite software version 1.5 [35,36] (Broad Institute,
Boston, MA) in both the reference and the FARMS clinical sets.
The raw intensity data from the AREDS as well as the Indian
cohort were analyzed using Partek Genomic Suite Version 6.4
(Partek Inc., MO, USA). The PennCNV algorithm [37] was used
to detect CNVs on the Illumina Bead Array data, e. g., the MPM
panel, the SiMES cohort and the custom Illumina panel.
Fosmid clones corresponding to CNP147 and CNP148 were
identified from the fosmid Human Genome Structural Variation
Project [38] based on the mapping of end-sequence pairs to the
regions (http://hgsv.washington.edu). Sites of structural variation
were confirmed by array comparative genomic hybridization using
corresponding test HapMap samples and the reference genome of
sample NA15510 [36]. Clones were recovered and inserts were
completely sequenced using Sanger-based capillary sequencing
[39]. The region between CFH and ASPM was screened using
polymerase chain reaction (PCR) to molecularly validate the
homozygous deletions detected by the Birdsuite program, and to
find additional large homozygous deletions, if any (Figure S11).
Primers were designed either manually or using Primer3 software
(http://frodo.wi.mit.edu/primer3/). We amplified a total of 30
fragments between CFH and ASPM either as single fragments or
multiple fragments using standard PCR with DNA from 10
HapMap CEU samples. We also screened 98 samples (49
Caucasians and 49 African Americans) from the Human Variation
panel, the entire FARMS cohort, and 443 of 511 AREDS samples
that were genotyped with both the Affymetrix 100 K and the
Illumina 100 K arrays.
Statistical Analysis
Haplotype Construction. We downloaded phase II HapMap
data for 305 SNPs located between CFH and CFHR5. A single JPT
sample (NA19012) with a large number of missing genotypes in this
region was not considered for haplotyping due to poor data
structure. Haplotypes, inferred using PHASE 2.2.1 [40,41] with a
population frequency of .0.5% were considered further. Identical
haplotypes were assigned the same number and all the haplotypes
were categorized in the order of similarity with an unweighted
group pairs method that uses arithmetic averages (UGPMA) using
the Molecular Evolutionary Genetics Analysis software version 4.0
(MEGA4) [42].
For the FARMS cohort, the haplotypes were constructed
manually according to the segregation pattern and missing alleles
were imputed by a parsimony method. After this, Mendelian
errors were identified at the haplotype level using MARKER-
INFO (S.A.G.E. version 5.3) and haplotypes with a frequency of
.1% were considered for further analysis. For the case-control
cohorts, two most likely PHASE 2.1.1 inferred haplotypes were
selected from each individual and haplotypes with a frequency of
.1% were examined further.
Linkage Disequilibrium (LD) Analysis in HapMap
Samples. We examined the LD structure between these CNPs
and the SNPs located at the RCA gene cluster using Haploview
version 4.0 [43]. For this, we picked the two most likely haplotypes
inferred by PHASE from each of 209 unrelated HapMap samples.
Imputation. To maximize the number of available markers,
we imputed the untyped genotypes using the MACH program
version 1.0 [44] with HapMap CEU haplotypes as the reference to
obtain much denser data.
Association Analysis. The SNPs located between CFH and
ZBTB41 that passed quality control metrics were tested for
association, with the minor allele as reference. For the deletion
variants and the haplotypes, the total number of copies present
(N=0, 1 or 2) was tested against the affection status. When
rs1329428 and rs203687 were included in association models as
SNP covariates, they were coded in a similar manner. For the
FARMS cohort, the original 15-level phenotype measurement of
Wisconsin age-related maculopathy grading system (WARMGS)
score was adjusted to age 80 using a Box-Cox transformation
method as previously described [2]. To account for the linear and
non-linear effects of age, we adjusted for both age and age
2 (age
squared). Family-based association analysis on the FARMS data
was conducted using the age-adjusted scores as the disease trait
using the ASSOC program (S.A.G.E. version 5.3), with each SNP
was tested for association under the additive mode of inheritance
in the presence of a random sibship effect. Single SNP association
analysis for the MPM panel is described elsewhere [45]. For other
case-control cohorts, logistic regression, as implemented in PLINK
[46], was used to test the association of SNPs (covariates used are
described in Table S8). For haplotype association analysis, the
number of copies of every haplotype except H2 were included
simultaneously using H2 as baseline and this results in estimates of
the effect of each haplotype relative to the base haplotype H2.
Since cases and controls included in the custom Illumina panel
were identified at different sites over differing time frames, we were
concerned about heterogeneity. Therefore, each cohort was
analyzed separately and the results combined using meta-analysis.
This approach is more conservative than a pooled analysis
grouping all cases and controls. To combine findings from
different cohorts, a joint effect estimate was calculated by taking
a weighted average of the individual cohort estimates, with the
inverse of the variance as the weighting factor. This combined
estimate was used to determine an overall odds ratio for each SNP
and its standard error, from which the p-value was calculated
assuming normality of the distribution.
Finding an Optimal SNP Set. In order to rank the best
SNPs in the 32 kb region and to conduct a minimal SNP set
explaining the effect of the region on AMD, we ran forward
selection. SNP genotypes (imputed) in the pooled set containing
the three Caucasian case-control datasets (the custom Illumina
panel, the MPM panel and the AREDS cohort) were coded as the
number of minor alleles, and were added one at a time as
predictors in a logistic regression model, including age and sex as
covariates. At each step, the SNP giving the smallest p value was
retained in the model, until no additional SNP remained
significantly associated (p,0.05).
Functional Analysis
We used two programs, AliBaba version 2.1 (http://www.gene-
regulation.com/pub/ programs.html) and Eldorado (Genomatix
software Inc. MI, USA) to examine the two important intronic
SNPs in the 32 kb core region. These programs enable us to
predict if changes in the nucleotide at this position, alters the
binding properties of the transcription factors. The amino acid
sequence around codon 402 of human CFH protein was compared
to that of other species using protein blast at the NCBI website.
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We downloaded gene expression data for Epstein-Barr Virus
transformed B cell lines (GENEVAR project, http://www.sanger.
ac.uk/humgen/genevar/) of 210 unrelated HapMap individuals,
which consisted of 60 parents of CEU, 45 CHB, 45 JPT, and 60
parents of YRI. We examined the effect of AMD-associated SNPs
on expression of CFH and CFH-related genes, CFHR1-CFHR5.T o
avoid population stratification due to differences in allele frequen-
cies among different ethnic groups, we tested association separately
in each population using linear regression. Effects (regression
coefficients) and p- values from regression results were combined by
meta-analysis using the METAL program (http://www.sph.umich.
edu/ csg/abecasis/Metal/index.html), which calculates an overall
Z-statistic and p-value from the weighted average of the individual
statistics by accounting for sample size in each sample.
Supporting Information
Figure S1 Segmental duplications in the RCA gene cluster. (A)
Predicted/known segmental duplications as shown in UCSC
human genome browser (NCBI Build 36, as of December 2008) as
well as in the literature. Homologous regions are indicated by
horizontal shaded bars of the same color. (B) Predicted segmental
duplications based on sequence similarity as shown by megablast
(NCBI). Highly similar regions are indicated with colored bars (see
Table S1 for more detail). The homologous regions encompass-
ing sequences identical to Y402H of CFH and the surrounding
region are shown in red bars. A major proportion of SNPs (2043/
2771) located at RCA gene clusters fall within these segmental
duplications.
(TIF)
Figure S2 Depth of coverage analysis of whole genome shotgun
sequence aligned to the reference genome predicts Venter may
have partial deletion of CFHR1 when compared to Watson, but
Watson has a predicted duplication of CFHR4 (regions in red
depict areas of excess depth of coverage).
(TIF)
Figure S3 Confirmation of homozygous deletions at CNP147
using the PCR-based deletion screening protocol (see Figure S11
for primers location). Gel picture of fragment Unique 01 showing
no band in HapMap CEU samples (a) and in samples from Coriell
human diversity panel (b) predicted to have both copies of
CNP147 deleted.
(TIF)
Figure S4 Arrangement of haplotypes derived from three
different HapMap groups in the order of similarity. Haplotypes
highlighted with yellow are the ones carrying deletion either at
CNP147 or CNP148. All the haplotypes are categorized according
to haplogroups observed in our clinical datasets (see figure 2 in the
main paper for more information). DCNP147 occurs on multiple
clades in the Yorubans, suggesting recurrent origin. Although this
deletion occurs on two different clades in CEU, they appeared to
be separated by recombination event within the CNP148 region.
DCNP148 occurs on multiple haplotype background both in
Asians and Yorubans.
(DOC)
Figure S5 PCR amplification of fragments (a) Unique 01, (b)
Frag_00.7.4 & Frag_B1_2.2, and (c) Frag_R3.05 & Frag_R1.13
confirming homozygous deletions in FARMS samples.
(TIF)
Figure S6 Gel pictures of fragments. DCNP147 carrying
haplotypes were predicted using allele ‘‘A’’ of rs2019727 because
none of the deletion-specific SNPs were genotyped in AREDS.
rs2019727 is in very strong LD with DCNP147 (r
2=0.9) in the
Caucasian reference sets. Predicted homozygous deletions at
CNP147 in AREDS samples were confirmed using PCR-based
deletion screening protocol. Amplification of fragments (a) Unique
01 and (b) Frag_R3.05 & Frag_R1.13 confirmed the homozygous
deletions in AREDS samples (as indicated by arrows).
(TIF)
Figure S7 Locations of the Cis-elements, as predicted by
chromatin immunoprecipitation assay, at CFH locus. This data
was obtained from UCSC Human genome browser. Arrow
indicates the transcriptional binding sites detected at rs203687 and
rs1329428.
(TIF)
Figure S8 Comparative primate genome analysis (depth of
coverage and interspecific arrayCGH) suggests that chimps have
more extensive duplication architecture than humans, and that
duplications likely arose in a common ancestor of chimp and
human but after divergence from orangutan (6–12 million years
ago). Targeted arrayCGH of the region confirms increase of
CFHR copies in chimpanzee (PTR) and bonobo (PPA) when
compared to human but that orangutan (PPY) has reduced copy-
number. Interestingly, a portion of CFHR4 seems to have
hyperexpanded in great apes (bonobo and orangutan).
(TIF)
Figure S9 Evolutionary conservation of codon 402 of CFH.
Neither Tyrosine nor Histidine at codon 402 is conversed in other
species. Arrow shows the codon 402 of CFH.
(TIF)
Figure S10 Study design. This study consisted of several stages.
In the first stage, structural variation at RCA gene cluster were
detected in the reference sets. The variations found in .1% of the
population, called copy number polymorphisms (CNP), were
characterized. In the second stage the significance of these CNPs
on AMD was examined in the clinical sets. In the third stage,
haplotypes were constructed using CNP and SNP genotypes and
the haplotypes over 1% frequency were tested for association with
AMD. Information from these haplotypes was used to fine map
the critical region. In the fifth stage, best SNP was selected from
this critical region by conditional analysis. In addition, we also
tested effect of these CNPs and AMD-associated SNPs on the
expression of genes involved in complement regulation. Finally,
functional studies were conducted for one of the AMD-associated
SNP affecting the CFH gene expression.
(TIF)
Figure S11 Schematic representation of PCR-based deletion
screening plan. The region of interest was divided into three
subregions, 1–3. Subregion 1 spanned CNP147; subregion 2
spanned the region between the 59 end of the CFH gene and 59
end of CNP147; and subregion 3 was defined as the region from
the 39 end of CNP147 to the middle of ASPM.( a) Enlargement of
region around unique region 01. Megablast search at CNP147
revealed a unique region that did not show homology to any other
regions in the genome. It is located at 195,066,977–195,010,019.
(b) Arrangement of genes in the RCA gene cluster, with the arrow
indicating the 59-39 direction. The vertical arrows indicate the
locations screened; three subregions are indicated with different
colors of arrows: blue arrows represent the subregion 01, which
includes CNP147. Subregions 2 and 3 are indicated with black
and red arrows, respectively.
(TIF)
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cluster, as identified through Megablast search.
(XLS)
Table S2 Rare structural variations detected among reference
sets.
(XLS)
Table S3 Frequency distribution of variations at CNP147 and
CNP148 in different reference populations.
(XLS)
Table S4 Association of six different haplotypes of CFH region
with AMD in the custom illumina panel.
(XLS)
Table S5 Meta-analysis SNPs located in the 32 kb critical
region.
(XLS)
Table S6 Variations at CNPs 147 and 148 detected with
PennCNV in the custom illumina panel.
(XLS)
Table S7 Rare structural variations in the RCA gene cluster in
FARMS cohort.
(XLS)
Table S8 Summary of SNP genotyping, genotype calling and
quality control measures used in this study.
(XLS)
Text S1 BLAST alignment of sequences surrounding some of
the AMD-associated SNPs in the RCA gene cluster with their
paralog sequences.
(DOC)
Text S2 Supplementary methods.
(DOC)
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